Literature DB >> 31330513

Survivin Impairs the Apoptotic Machinery in CD4+ T Cells of Patients with Ulcerative Colitis.

Bai-Sui Feng1, Na Ma1, Yuan-Yi Zhang2, Han Gao3, Cui Zhang3, Gengfeng Li3, Zhanju Liu3, Yisheng Feng4, Hai-Qiong Yu5, Liang Xiao6, Zhi-Gang Liu2, Ping-Chang Yang7.   

Abstract

BACKGROUND: The increase in CD4+ T cell infiltration and overproduction of CD4+ T cell-associated cytokines have been observed in the inflamed colon mucosa of patients with ulcerative colitis (UC); the underlying mechanisms are not fully understood. Survivin plays a critical role in the interference with apoptotic machinery. This study aims to elucidate the role of survivin in the interference with the apoptotic machinery in CD4+ T cells of UC patients.
METHODS: Peripheral blood samples were collected from UC patients (UC group) and healthy subjects (healthy group). The apoptotic status in CD4+ T cells was analyzed by flow cytometry.
RESULTS: We observed that the expression of survivin was significantly higher in CD4+ T cells of UC patients than in healthy subjects. UC CD4+ T cells were resistant to apoptosis induction. A complex of survivin and c-Myc, the transcription factor of FasL, was detected in CD4+ T cells in UC patients, which prevented the binding of c-Myc to the FasL promoter and interfered with the expression of FasL. Increased expression of survivin prevented the activation-induced CD4+ T cells from apoptosis.
CONCLUSIONS: The data indicate that UC CD4+ T cells express high levels of survivin, which impairs the apoptotic machinery in CD4+ T cells and prevents the activation-induced CD4+ T cell apoptosis. Therefore, target therapy against survivin has translational potential in the treatment of UC patients.
© 2019 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Keywords:  Apoptosis; Colitis; Immunity; Intestine; Lymphocyte

Mesh:

Substances:

Year:  2019        PMID: 31330513      PMCID: PMC7265744          DOI: 10.1159/000500546

Source DB:  PubMed          Journal:  J Innate Immun        ISSN: 1662-811X            Impact factor:   7.349


  24 in total

Review 1.  Ulcerative colitis.

Authors:  Silvio Danese; Claudio Fiocchi
Journal:  N Engl J Med       Date:  2011-11-03       Impact factor: 91.245

Review 2.  T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production.

Authors:  Jinfang Zhu
Journal:  Cytokine       Date:  2015-06-01       Impact factor: 3.861

Review 3.  Survivin in autoimmune diseases.

Authors:  G Gravina; C Wasén; M J Garcia-Bonete; M Turkkila; M C Erlandsson; S Töyrä Silfverswärd; M Brisslert; R Pullerits; K M Andersson; G Katona; M I Bokarewa
Journal:  Autoimmun Rev       Date:  2017-05-28       Impact factor: 9.754

Review 4.  Targeting the Fas/FasL signaling pathway in cancer therapy.

Authors:  María Villa-Morales; José Fernández-Piqueras
Journal:  Expert Opin Ther Targets       Date:  2012-01-12       Impact factor: 6.902

Review 5.  Biomarkers of Inflammation in Inflammatory Bowel Disease.

Authors:  Bruce E Sands
Journal:  Gastroenterology       Date:  2015-07-09       Impact factor: 22.682

6.  Transgenic expression of survivin compensates for OX40-deficiency in driving Th2 development and allergic inflammation.

Authors:  Fengyang Lei; Jianyong Song; Rizwanul Haque; Xiaofang Xiong; Deyu Fang; Yuzhang Wu; Susanne M A Lens; Michael Croft; Jianxun Song
Journal:  Eur J Immunol       Date:  2013-05-28       Impact factor: 5.532

7.  Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis.

Authors:  Ivan J Fuss; Frank Heller; Monica Boirivant; Francisco Leon; Masaru Yoshida; Stefan Fichtner-Feigl; Zhiqiong Yang; Mark Exley; Atsushi Kitani; Richard S Blumberg; Peter Mannon; Warren Strober
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

Review 8.  Survivin: A molecular biomarker in cancer.

Authors:  Praveen Kumar Jaiswal; Apul Goel; R D Mittal
Journal:  Indian J Med Res       Date:  2015-04       Impact factor: 2.375

9.  The Effects of Armillarisin A on Serum IL-1β and IL-4 and in Treating Ulcerative Colitis.

Authors:  Ping Wu; Yonggao Guo; Fangyuan Jia; Xiuli Wang
Journal:  Cell Biochem Biophys       Date:  2015-05       Impact factor: 2.194

10.  NLRP3 inflammasome has a protective effect against oxazolone-induced colitis: a possible role in ulcerative colitis.

Authors:  Shigehiro Itani; Toshio Watanabe; Yuji Nadatani; Naoki Sugimura; Sunao Shimada; Shogo Takeda; Koji Otani; Shuhei Hosomi; Yasuaki Nagami; Fumio Tanaka; Noriko Kamata; Hirokazu Yamagami; Tetsuya Tanigawa; Masatsugu Shiba; Kazunari Tominaga; Yasuhiro Fujiwara; Tetsuo Arakawa
Journal:  Sci Rep       Date:  2016-12-14       Impact factor: 4.379

View more
  2 in total

1.  Once upon a Time.

Authors: 
Journal:  J Innate Immun       Date:  2020-05-15       Impact factor: 7.349

Review 2.  Dysregulation of Survivin-Targeting microRNAs in Autoimmune Diseases: New Perspectives for Novel Therapies.

Authors:  Navid Shomali; Marwah Suliman Maashi; Behzad Baradaran; Amin Daei Sorkhabi; Aila Sarkesh; Hamed Mohammadi; Maryam Hemmatzadeh; Faroogh Marofi; Siamak Sandoghchian Shotorbani; Mostafa Jarahian
Journal:  Front Immunol       Date:  2022-03-03       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.